Formosa Pharmaceuticals is a is a clinical stage biopharmaceutical company with primary focus in the areas of ophthalmology and oncology.
News Highlight
- Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization
- Formosa Pharmaceuticals and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the treatment of Acute Dry Eye Disease in the U.S.
- Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
Formosa Pharma is developing a unique pipeline consisting of risk-diverse development modes, including 505(b)(2), biosimilars, and NCEs. Our proprietary APNT® nanoparticle formulation platform, from which lead program APP13007 is derived, is available for application to drug candidates in need of improving pharmacokinetics and bioavailability.
